Author | Walter M. Stadler, MD, FACP

Articles

Renal Cancer Therapeutics: Now What?

March 13, 2012

The development of vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors for the treatment of renal cancer is a real success story.